Evidence mapPaperPMID 39479625Full record

ArticleFood science & nutrition2024

Luteolin ameliorates hyperuricemic nephropathy by activating urate excretion and Nrf2/HO-1/NQO1 antioxidant pathways in mice.

Huifan Yu, Linsheng Huang, Lili Gui, Zhengkun Wu, Han Luo, Mao Xu, Yan Zhang, Yongshuai Qian, Wenjie Cao, Li Liu and 1 more

Abstract read
In one paragraph

Article in Food science & nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huifan YuSchool of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research Hubei University of Medicine Shiyan Hubei China.ORCID https://orcid.org/0000-0003-2936-5778
Linsheng HuangDepartment of Hepatopancreatobiliary Surgery, Taihe Hospital Hubei University of Medicine Shiyan Hubei China.
Lili GuiSchool of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research Hubei University of Medicine Shiyan Hubei China.
Zhengkun WuSchool of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research Hubei University of Medicine Shiyan Hubei China.
Han LuoSchool of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research Hubei University of Medicine Shiyan Hubei China.
Mao XuSchool of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research Hubei University of Medicine Shiyan Hubei China.
Yan ZhangSchool of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research Hubei University of Medicine Shiyan Hubei China.
Yongshuai QianSchool of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research Hubei University of Medicine Shiyan Hubei China.
Wenjie CaoSchool of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research Hubei University of Medicine Shiyan Hubei China.
Li LiuSchool of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research Hubei University of Medicine Shiyan Hubei China.
Fei LiSchool of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research Hubei University of Medicine Shiyan Hubei China.ORCID https://orcid.org/0000-0003-2016-6422

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Luteolin is a natural flavonoid, which exists in many plants, including onions, broccoli, carrots, peppers, celery, olive oil, and mint. Luteolin is a dietary flavonoid with potent uric acid-lowering and antioxidant bioactivities. To date, the mechanism by which luteolin alleviates hyperuricemia nephropathy (HN) still needs to be better defined. This study aims to evaluate the therapeutic efficacy of luteolin in a preclinical mouse model and in vitro. Luteolin was administered in the HN mice induced by the combination of potassium oxonate and hypoxanthine to evaluate the potential renoprotective effects in vivo. The NRK-52E cells were stimulated with adenosine for in vitro evaluation. Hematoxylin and eosin staining, biochemical analysis, immunoblotting, immunofluorescence, and immunohistochemistry were performed for the histopathologic and mechanistic investigations. The results suggest that luteolin attenuated tubular dilation and epithelial atrophy in the renal tissue of HN mice. Further, luteolin improved biochemical indicators concerning renal functions and oxidative stress in vivo. Mechanistically, luteolin reduced the renal expressions of KIM-1 and caspase-3. Luteolin activated renal SIRT1/6 cascade and its downstream Nrf2-mediated antioxidant pathway. Furthermore, luteolin elevated the renal expressions of ATP-binding cassette subfamily G isoform 2 protein (ABCG2) and organic anion/cation transporters. In addition, livers of luteolin-treated HN mice exhibited robust inhibition of xanthine oxidase. Together, our study shows that luteolin alleviates renal injury in the HN mice by activating urate excretion and Nrf2/HO-1/NQO1 antioxidant pathways and inhibiting liver xanthine oxidase activity. Thus, luteolin may be a potential agent for the treatment of HN.

Indexed as

hyperuricemic nephropathyKIM‐1luteolinNrf2uric acid transporters

Identifiers

PMID39479625
PMCPMC11521689

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.